DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update
Aug 13, 2024, 16:01 ET – FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis – Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design – Seeking to Initiate Phase 3 Trial in 2024 with Topline Results Expected in 2H 2026 – Webcast of Earnings Call […]
DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update Read More »